Table 1 Changes in cardiovascular risk factors and medications used by gender

Men

 Smoker’s, n (%)^†‡§||

20 (29)

20 (29)

14 (20)

14 (20)

 Ischemic heart disease n (%)

8 (11)

8 (12)

9 (13)

9 (13)

 Cerebrovascular disease n (%)

2 (3)

2 (3)

2 (3)

3 (4)

 BMI (kg/m²)

30.0 ± 4.1

30.3 ± 4.2

30.4 ± 4.4

30.3 ± 4.5

 Total cholesterol (mg/dL)^‡

198.3 ± 39.3

191.5 ± 41.6

188.9 ± 36.7

183.4 ± 34.4

 Tryglicerides (mg/dL)

160.6 ± 65.6

153.9 ± 92.8

153.5 ± 101.2

151.7 ± 129.2

 LDL cholesterol (mg/dL)^‡

121.5 ± 36.2

114.6 ± 34.9

110.6 ± 34.8

109.2 ± 32.9

 HDL cholesterol (mg/dL)^†‡§||

44.6 ± 9.2

45.4 ± 10.0

48.1 ± 11.4

48.3 ± 11.7

 Atherogenic index^†‡||

4.6 ± 1.3

4.4 ± 1.5

4.2 ± 1.3

4.0 ± 1.2

 Serum glucose (mg/dL)

111.4 ± 32.3

115.3 ± 43.8

112.1 ± 40.7

114.1 ± 37.4

 HbA1c (%)

6.36 ± 1.23

6.51 ± 1.34

6.51 ± 1.06

6.46 ± 1.08

 HOMA-IR

3.2 ± 2.3

4.3 ± 10.5

2.2 ± 1.9

3.0 ± 2.2

 Office SBP (mm Hg)*^‡¶

141 ± 11

134 ± 15

138 ± 16

132 ± 16

 Office DBP (mm Hg)*^†‡||¶

86 ± 10

81 ± 9

82 ± 10

77 ± 9

 Mean blood pressure (mmHg)^‡||¶

101 ± 11

99 ± 10

101 ± 10

96 ± 10

 Mean Antihypertensive drugs*^†‡

1.07 ± 1.06

1.49 ± 1.26

1.61 ± 1.32

1.64 ± 1.31

 Antihypertensive drugs n (%)^†‡

42 (60.9)

50 (72.5)

51 (73.9)

52 (75.4)

 Mean Lipid lowering drugs^†‡

0.54 ± 0.53

0.62 ± 0.55

0.68 ± 0.61

0.68 ± 0.58

 Lipid lowering drugs n (%)^†‡

36 (52.2)

41 (59.4)

42 (60.9)

43 (62.3)

 Mean antidiabetic drugs^†‡

0.75 ± 0.81

0.83 ± 0.82

0.91 ± 0.92

0.86 ± 0.88

 Antidiabetic drugs, n (%)

38 (55.1)

42 (60.9)

42 (60.9)

42 (60.9)

Women

 Smoker’s, n (%)

5 (12.2)

5 (12.2)

5 (12.2)

5 (12.2)

1.00

 Ischemic heart disease, n (%)

2(5)

2 (5)

3 (7)

3 (7)

0.392

 Cerebrovascular disease, n (%)

0

0

0

0

–

 BMI (kg/m²)

30.0 ± 4.1

30.3 ± 4.2

30.4 ± 4.4

30.3 ± 4.5

0.526

 Total cholesterol (mg/dL)

204.1 ± 43.8

201.2 ± 37.4

196.2 ± 26.8

188.4 ± 27.2

0.099

 Tryglicerides (mg/dL)

140.8 ± 58.7

129.9 ± 40.5

138.4 ± 61.1

129.6 ± 50.5

0.671

 LDL cholesterol (mg/dL)

121.9 ± 37.5

121.8 ± 31.1

112.8 ± 25.6

109.9 ± 24.0

0.084

 HDL cholesterol (mg/dL)^†§

51.9 ± 13.6

53.5 ± 13.6

55.8 ± 14.1

53.3 ± 11.4

0.027

 Atherogenic index

4.1 ± 1.1

3.9 ± 1.0

3.7 ± 1.1

3.7 ± 1.1

0.069

 Serum glucose (mg/dL)

116.7 ± 34.7

114.5 ± 39.3

117.4 ± 40.4

110.6 ± 28.9

0.606

 HbA1c (%)

6.37 ± 1.11

6.39 ± 1.04

6.53 ± 1.04

6.51 ± 1.04

0.220

 HOMA-IR

3.1 ± 2.5

4.2 ± 11.6

2.9 ± 5.0

2.6 ± 2.2

0.175

 Office SBP (mm Hg)

134 ± 17

133 ± 21

131 ± 15

131 ± 17

0.738

 Office DBP (mm Hg)^‡

83 ± 12

81 ± 12

78 ± 10

77 ± 10

<0.001

 Mean Blood Pressure (mmHg)

97 ± 10

98 ± 13

97 ± 10

95 ± 11

0.260

 Mean Antihypertensive Drugs

1.46 ± 1.27

1.54 ± 1.12

1.78 ± 1.17

1.66 ± 0.94

0.133

 Antihypertensive Drugs n (%)^†

29(70.7)

32 (78.0)

34 (82.9)

36 (87.8)

<0.001

 Mean Lipid lowering drugs^‡||

0.56 ± 0.59

0.56 ± 0.59

0.68 ± 0.57

0.71 ± 0.56

0.017

 Lipid lowering drugs, n (%)^†‡

21 (51.2)

22 (53.7)

26 (63.4)

27 (65.9)

0.033

 Mean antidiabetic drugs^†

0.95 ± 0.97

0.85 ± 0.96

1.04 ± 1.07

0.93 ± 0.96

0.108

 Antidiabetic drugs, n (%)

24 (60.9)

24 (60.9)

24 (60.9)

24 (60.9)

1.000